BACKGROUND: In @entity1 with @entity12040 , circulating lymphocytes are activated, and histological findings indicate that cell-mediated immunity plays an important role in the pathogenetic sequence leading to @entity455 . METHODS AND RESULTS: To delineate the profile of inflammatory and chemoattractant cytokines involved in T-cell activation in @entity12040 , we measured by ELISA serum levels of @entity650 , @entity1356 , and @entity5737 in 18 @entity1 . Subsequently, we wanted to establish whether any of these molecules could be used as a marker to monitor the clinical course of the disease and to predict disease exacerbations. We found that all @entity1 with @entity12040 studied during an active phase of the disease have increased serum concentration of @entity650 compared with healthy control subjects (P<0.01). Enhanced @entity650 serum levels paralleled disease activity to the extent that its serum concentrations were comparable to those of control subjects when @entity1 were studied in remission. @entity5737 concentrations were also higher than normal in the serum of all @entity1 with @entity12040 (P<0.01) studied during an active phase of the disease. @entity5737 serum levels tended to normalize in remission, but values remained higher than those of control subjects (P<0.05). In contrast, serum concentrations of @entity1356 were below the detection limit of ELISA in both healthy subjects and all @entity1 with @entity12040 . A positive correlation was found between either @entity650 (rho=0.705, P<0.01) or @entity5737 (rho=0.607, P<0.05) serum level and disease activity. CONCLUSIONS: The close correlation of serum @entity650 and @entity5737 levels with disease activity suggests that these cytokines contribute to @entity75 in @entity12040 and raises the possibility that their monitoring in serum helps clinicians find adequate treatment adjustments in individual @entity1 .

@entity650 and @entity5737 in XXXX : a guide for therapeutic decisions?

@entity1 :: ('9606', 'Species') :: ['patients'] @entity650 :: ('3569', 'Gene') :: ['IL-6', 'interleukin (IL)-6'] @entity455 :: ('MESH:D014652', 'Disease') :: ['vascular lesions'] @entity5737 :: ('6352', 'Gene') :: ['RANTES'] @entity1356 :: ('3553', 'Gene') :: ['IL-1beta'] @entity75 :: ('MESH:D001927', 'Disease') :: ['vasculitic lesions'] @entity12040 :: ('MESH:D013625', 'Disease') :: ['Takayasu arteritis']
@entity12040 :: (MESH:D013625,Disease) :: ['Takayasu arteritis']
